Browse by author
Lookup NU author(s): Dr Steve Parry,
Dr Thomas Chadwick,
Dr Janine Gray,
Dr Rodney Bexton,
Dr John Bourke
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Design: Pilot cohort study. Methods: Patients-(i) Bradycardia-pacing group: Consecutive patients referred for pacing for SND, AVB and CSS; (ii) Consecutive head-up tilt (HUT)-positive VVS patients. Controls-(i) Simple controls (S-Con: normal examination/ECG) and (ii) Electrophysiology controls (EP-Con: consecutive subjects referred for accessory pathway ablation). Pacing referrals and EP-Con had electrophysiology studies to confirm referral diagnosis and exclude others. All subjects had bolus injection of 20 mg intravenous adenosine during continuous ECG and blood pressure monitoring (positive test: >= 6 s asystole, >= 10 s high-degree AVB post-injection). Sensitivity, specificity, safety and tolerability of the test were measured. Results: Of 264 potential participants (4 SND, 8 AVB, 7 CSS, 10 VVS, 10 EP-Con and 11 S-Con) 50 were studied. All (100%) of the bradycardia-pacing group were adenosine test-positive, as were 6 (60%) VVS. None (0%) and 3 (27%) of the EP- and S-Con groups were positive. Adenosine testing was 100% sensitive and 86% specific for bradycardia-pacing indications, and 100% specific using the diagnostically 'clean' EP-Con results. There were no significant adverse or side effects. Conclusions: Adenosine testing reliably identified patients with definitive bradycardia-pacing indications in whom alternative diagnoses were excluded. Further work is needed to evaluate the role of this test in the diagnosis of unexplained syncope.
Author(s): Parry SW, Chadwick T, Gray JC, Bexton RS, Tynan M, Bourke JP, Nath S
Publication type: Article
Publication status: Published
ISSN (print): 1460-2725
ISSN (electronic): 1460-2393
Publisher: Oxford University Press
Altmetrics provided by Altmetric